 |
|
Respiratory Infections With Pseudomonas aeruginosa in Children With Cystic Fibrosis
Early Detection by Serology and Assessment of Risk Factors
Susan E. H. West, PhD;
Lan Zeng, MS;
Bee Leng Lee, PhD;
Michael R. Kosorok, PhD;
Anita Laxova, BS;
Michael J. Rock, MD;
Mark J. Splaingard, MD;
Philip M. Farrell, MD,PhD
JAMA. 2002;287:2958-2967.
Context Patients with cystic fibrosis (CF) are susceptible to lower respiratory tract infections with Pseudomonas aeruginosa and typically acquire this organism in early childhood. Once P aeruginosa infection is established, eradication may be impossible, and progressive lung disease often aggravates morbidity and mortality risks. The ability to diagnose CF by genetic testing at birth makes it possible to determine the temporal sequence of events that result in P aeruginosa–associated pulmonary infections.
Objective To evaluate the longitudinal relationship between the production of an antibody response against P aeruginosa and clinical factors associated with P aeruginosa pulmonary infections in patients with CF diagnosed in early life.
Design, Setting, and Patients Serum samples and oropharyngeal cultures (protocol cultures) were obtained at 6-month intervals from April 15, 1985, to April 15, 2000 (or for up to 180 months depending on their enrollment date) from 68 patients at 2 centers in Madison and Milwaukee, Wis, diagnosed through the Wisconsin CF Neonatal Screening Project, a longitudinal cohort study. Additional cultures were obtained at examining physicians' discretion (all cultures).
Main Outcome Measures Time to serum IgG, IgA, and IgM antibody titer of at least 1:256 against P aeruginosa, assessed by enzyme-linked immunosorbent assay using cell lysate, exotoxin A, and elastase as antigens; time to organism isolation from respiratory samples; time to Wisconsin Cystic Fibrosis Radiograph (WCXR) score of 5 or more.
Results The median time to an antibody titer of at least 1:256 was 17.8, 24.2, and 70.9 months for cell lysate, exotoxin A, and elastase, respectively. The rise of anti–cell lysate and anti–exotoxin A titers to 1:256 or more occurred a mean of 11.9 (P<.001) and 5.6 (P = .04) months, respectively, before the isolation of P aeruginosa for all cultures and 18.2 (P<.001) and 11.9 (P = .006) months, respectively, before protocol cultures. There was no significant difference between the rise of anti–cell lysate and anti–exotoxin A titer and a WCXR score of 5 or more (P = .24 and .32, respectively). Treatment with long-term, non-Pseudomonas oral antibiotics and integration of CF infants with older, chronically infected patients were associated with a significantly increased risk of P aeruginosa pulmonary infection.
Conclusions In CF patients diagnosed through neonatal screening, P aeruginosa pulmonary infections occurred 6 to 12 months before the organism was isolated from respiratory secretions. The longitudinal monitoring of P aeruginosa antibody titers, in concert with WCXR score, should facilitate diagnosis and treatment of P aeruginosa pulmonary infections in young children with CF.
Author Affiliations: Department of Pathobiological Sciences and School of Veterinary Medicine (Dr West), Departments of Pediatrics (Drs Kosorok, Rock, and Farrell, and Mss Laxova and Zeng) and Biostatistics and Medical Informatics (Drs Lee and Kosorok and Ms Zeng), Medical School, University of Wisconsin, Madison; and Department of Pediatrics, Medical College of Wisconsin, Milwaukee (Dr Splaingard).
RELATED ARTICLE
June 12, 2002
JAMA. 2002;287(22):3017-3018.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
NKG2D Is Critical for NK Cell Activation in Host Defense against Pseudomonas aeruginosa Respiratory Infection
Wesselkamper et al.
J. Immunol. 2008;181:5481-5489.
ABSTRACT
| FULL TEXT
Immunoproteomics To Examine Cystic Fibrosis Host Interactions with Extracellular Pseudomonas aeruginosa Proteins
Upritchard et al.
Infect. Immun. 2008;76:4624-4632.
ABSTRACT
| FULL TEXT
Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease
Murphy et al.
Am. J. Respir. Crit. Care Med. 2008;177:853-860.
ABSTRACT
| FULL TEXT
Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis
Mayer-Hamblett et al.
Proc Am Thorac Soc 2007;4:370-377.
ABSTRACT
| FULL TEXT
Detection of antibodies to Pseudomonas aeruginosa in serum and oral fluid from patients with cystic fibrosis
Weisner et al.
J Med Microbiol 2007;56:670-674.
ABSTRACT
| FULL TEXT
Cystic Fibrosis and Other Respiratory Diseases of Impaired Mucus Clearance
Livraghi and Randell
Toxicol Pathol 2007;35:116-129.
ABSTRACT
| FULL TEXT
Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis
Kappler et al.
Thorax 2006;61:684-688.
ABSTRACT
| FULL TEXT
Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population
Tramper-Stranders et al.
Thorax 2006;61:689-693.
ABSTRACT
| FULL TEXT
Pseudomonas serology: confusion, controversy, and challenges
Farrell and Govan
Thorax 2006;61:645-647.
FULL TEXT
Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre.
Proesmans et al.
Eur Respir J 2006;27:937-943.
ABSTRACT
| FULL TEXT
Eradication of Pseudomonas aeruginosa in cystic fibrosis patients.
Doring et al.
Eur Respir J 2006;27:653-653.
FULL TEXT
Early Immune Response to the Components of the Type III System of Pseudomonas aeruginosa in Children with Cystic Fibrosis
Corech et al.
J. Clin. Microbiol. 2005;43:3956-3962.
ABSTRACT
| FULL TEXT
Longitudinal Development of Mucoid Pseudomonas aeruginosa Infection and Lung Disease Progression in Children With Cystic Fibrosis
Li et al.
JAMA 2005;293:581-588.
ABSTRACT
| FULL TEXT
Use of Phage Display To Identify Potential Pseudomonas aeruginosa Gene Products Relevant to Early Cystic Fibrosis Airway Infections
Beckmann et al.
Infect. Immun. 2005;73:444-452.
ABSTRACT
| FULL TEXT
Serological Response to Pasteurella multocida NanH Sialidase in Persistently Colonized Rabbits
Sanchez et al.
CVI 2004;11:825-834.
ABSTRACT
| FULL TEXT
Clinically Feasible Biofilm Susceptibility Assay for Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis
Moskowitz et al.
J. Clin. Microbiol. 2004;42:1915-1922.
ABSTRACT
| FULL TEXT
Bronchopulmonary Disease in Children with Cystic Fibrosis after Early or Delayed Diagnosis
Farrell et al.
Am. J. Respir. Crit. Care Med. 2003;168:1100-1108.
ABSTRACT
| FULL TEXT
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson et al.
Am. J. Respir. Crit. Care Med. 2003;168:918-951.
ABSTRACT
| FULL TEXT
Development of a diagnostic PCR assay that targets a heat-shock protein gene (groES) for detection of Pseudomonas spp. in cystic fibrosis patients
Clarke et al.
J Med Microbiol 2003;52:759-763.
ABSTRACT
| FULL TEXT
|
